Summary: New research reveals a clear connection between gut health and post-COVID syndrome (PCS). The study finds that people with prior gastrointestinal issues are more likely to develop persistent post-viral fatigue. Analysis of blood, saliva and stool from PCS patients uncovered immune and gut-related biomarkers that point to ongoing inflammation and impaired intestinal barrier function.
Notably, altered IL-6 levels and an increased LBP/sCD14 ratio indicate chronic immune activation in many PCS patients. These results suggest that monitoring gut health and specific gut-related biomarkers could be important for predicting and managing long-term symptoms after COVID-19.
Key Facts:
- Immune changes: PCS patients demonstrated higher inflammatory markers, including elevated IL-6 and an increased LBP/sCD14 ratio.
- Gut health matters: Individuals with earlier gastrointestinal complaints were more likely to develop persistent post-viral fatigue following SARS-CoV-2 infection.
- Predictive potential: Tracking gastrointestinal symptoms and gut-related biomarkers may help identify patients at risk of PCS and guide earlier, targeted interventions.
Source: Medical University of Vienna
Researchers at the Medical University of Vienna have provided fresh evidence linking the gastrointestinal tract to the development of post-COVID syndrome (PCS).
Published in the journal Allergy, the study reports that PCS patients show altered inflammatory profiles and signs of intestinal barrier disruption, changes that can contribute to long-lasting fatigue after a viral infection.
The team, led by Eva Untersmayr-Elsenhuber at MedUni Vienna’s Center for Pathophysiology, Infectiology and Immunology, evaluated data from a prospective observational cohort. They reviewed clinical records to track gastrointestinal symptoms before, during and after SARS-CoV-2 infection and performed laboratory analyses on blood, saliva and stool to validate clinical observations biologically.
Their analysis found that people with pre-existing gastrointestinal complaints were more likely to develop PCS-associated fatigue. Biologically, PCS cases displayed increased LBP/sCD14 ratios and lower IL-33 levels—findings consistent with altered immune activation and compromised intestinal barrier integrity. Elevated IL-6 levels, a marker of systemic inflammation, were also more common in PCS patients.
“Our results suggest that SARS-CoV-2 infection can produce lasting disruptions in immune function and gut integrity that contribute to post-COVID symptoms,” says Eva Untersmayr-Elsenhuber, co-director of the National Reference Center for Postviral Syndromes at MedUni Vienna.
Toward targeted treatment strategies
The study emphasizes the central role of the gastrointestinal system in the emergence of long-term consequences after COVID-19. Systematic monitoring of GI symptoms together with targeted biomarker testing could identify patients at risk for PCS earlier and enable tailored treatment plans—especially for those struggling with post-viral fatigue.
Lead author Johanna Rohrhofer notes the significance of the findings: “Many of our participants were young and healthy before infection, and most had mild or asymptomatic initial illness. The group that later developed post-viral fatigue reported gastrointestinal complaints more frequently.”
The researchers plan further studies to confirm these associations and refine predictive markers. Identifying reliable biomarkers for PCS could support personalized prevention and therapeutic approaches in the future, helping to reduce the long-term burden of post-COVID conditions.
About this post COVID fatigue research news
Author: Karin Kirschbichler
Source: Medical University of Vienna
Contact: Karin Kirschbichler – Medical University of Vienna
Image: The image is credited to Neuroscience News
Original Research: Open access. “Gastrointestinal Barrier Disruption in Post-COVID Syndrome Fatigue Patients” by Eva Untersmayr-Elsenhuber et al., published in Allergy.
Abstract
Gastrointestinal Barrier Disruption in Post-COVID Syndrome Fatigue Patients
Background
Post-COVID Syndrome (PCS) describes persistent symptoms that some people experience after SARS-CoV-2 infection, regardless of whether the acute illness was asymptomatic, mild, or severe. Current estimates suggest a significant minority develop PCS following COVID-19. This study examined how SARS-CoV-2 affects the gastrointestinal tract and whether those effects associate with PCS features such as fatigue, post-exertional malaise (PEM), orthostatic or autonomic dysregulation, and cognitive difficulties.
Methods
The researchers combined prospective clinical data with symptom histories before, during and after infection to identify potential risk factors and predictive markers for PCS. Blood, saliva and stool samples from a well-characterized PCS cohort were analyzed to provide biological validation of clinical patterns and to investigate key immune and gut-related biomarkers.
Results
The study found a clear association between pre-existing gastrointestinal complaints and the later development of PCS-related fatigue. Compared with control groups, PCS patients showed higher LBP/sCD14 ratios, reduced IL-33 levels and elevated IL-6 concentrations. Together, these biomarker patterns point to low-grade intestinal inflammation, impaired gut barrier function and ongoing immune activation in many PCS cases.
Conclusion
The findings indicate that SARS-CoV-2 can disrupt innate immune pathways and gastrointestinal barrier integrity, resulting in low-grade intestinal inflammation and barrier leakage that may underlie PCS fatigue. Routine monitoring of gastrointestinal symptoms and specific biomarkers before, during and after infection could help identify predictive clinical phenotypes and guide earlier interventions. A better understanding of interactions between viral infection, immune response and gut health may lead to improved diagnostic and treatment strategies for people affected by PCS.